ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its...
Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding...
View ArticleANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against...
The Series A Complements Recent CARB-X Grant of up to $8,9 Million Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today...
View ArticleANTABIO Announces Key Executive Appointments
ANTABIO Announces Key Executive Appointments Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of...
View ArticleFirst publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor...
Antabio announces publication of a manuscript in Antimicrobial Agents and Chemotherapy: Discovery of a Novel Metallo-ß-Lactamase Inhibitor, which can Potentiate Meropenem Activity against...
View ArticleANTABIO Completes € 12.5M Series A
New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017 Antabio SAS, a biopharmaceutical company...
View ArticleMarc Lemonnier appointed at the Scientific Advisory Board of JPIAMR
Labège, 22 January 2019. We are pleased to announce that Antabio’s CEO Marc Lemonnier has been appointed as a new member of the Scientific Advisory Board (SAB) of JPIAMR. The Joint Programming...
View ArticleAntabio is seeking a Laboratory Assistant/Technician to join our discovery...
Antabio est une société biopharmaceutique située à Labège (31) dédiée à la découverte de traitements innovants anti-infectieux. Antabio dispose d’une équipe internationale avec une expertise...
View ArticleAntabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM...
Two presentations will focus on Antabio’s ANT2681, a novel Metallo β-Lactamase Inhibitor that restores the efficacy of Meropenem against clinical strains of NDM-producing CRE Labège, France, June 05,...
View ArticleAntabio Receives QIDP Designation from the U.S. FDA for the Development of...
Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681 Labège, France, 21 June 2019. Antabio SAS, a private biopharmaceutical company...
View ArticleAntabio applauds the new mechanism for reimbursement of antibiotics set up by...
Antabio applauds the new mechanism for reimbursement of antibiotics set up by CMS in the US On August 2, 2019, the US government announced several significant changes to hospital antibiotic...
View ArticleAntabio Awarded $4.4 Million from CARB-X for the Further Development of its...
The funding will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studies. Download the full press release hereTélécharger le...
View ArticleAntabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation...
Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem...
View ArticleAntabio is seeking a Clinical Pharmacologist
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleAntabio Awarded EUR 0.9 million funding from the Occitanie Region to support...
Télécharger le communiqué en version française The post Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel...
View ArticleLaunch of ARPEGE, a French multidisciplinary consortium to fight antibiotic...
Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project has been funded by the French government with nearly €9 million...
View ArticleAntabio Announces First Subjects Dosed in Phase 1 Clinical Trial of...
MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii....
View ArticleAntabio is seeking a Regulatory Manager
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleANTABIO Raises €25 million in Series B Financing
Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 up to completion...
View ArticleANTABIO Announces Appointment of Dr. Erick Lelouche as Chairman of the Board
Antabio SAS is pleased to announce the appointment of Dr. Erick Lelouche as Chairman of the Board of Directors. Download the full press release here The post ANTABIO Announces Appointment of Dr. Erick...
View ArticleAntabio is seeking a Clinical Project Manager
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View Article
